Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.77 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.77 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.60 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.60 |
| ▸ | FLT3 | P36888 | 3/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.60 |
| ▸ | MET | P08581 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | GRK5 | P34947 | 3/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.57 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.57 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.57 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16466791 | 0.91 | KDR (0.80) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| SCHEMBL16466793 | 0.91 | KDR (0.80) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| SCHEMBL16568048 | 0.90 | KDR (0.79) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| SCHEMBL16486735 | 0.90 | KDR (0.79) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| SCHEMBL2117954 | 0.87 | PDGFRB (0.81) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| SCHEMBL31672474 | 0.87 | PDGFRB (0.81) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL29354429 | 0.87 | PDGFRB (1.00) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| SCHEMBL13755224 | 0.87 | PDGFRB (0.81) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL2116670 | 0.87 | PDGFRB (1.00) | KDRPDGFRBFGFR1TLK2PRKAA1 | |
| SCHEMBL13755252 | 0.87 | KDR (0.81) | KDRPDGFRBFGFR1TLK2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-9539239-B1 | Compositions and methods for treatment of neurodegenerative disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-01-10 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-22 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2011119777-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367527-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE | CLN6, PSEN2, CHAT | KDR 4527/4885PDGFRB 3455/4885FGFR1 4629/4885 |
| US-20130217679-A1 | Compositions and Methods for Treatment of Neurodegenerative Disease | CLN6, PSEN2, CHAT | KDR 4527/4885PDGFRB 3455/4885FGFR1 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.